melatonin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases malondialdehyde (circulating)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The reduction in serum MDA in the melatonin group was also statistically significant when compared to the placebo group ( P = 0.03; Table 3).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.. - Study
- RCT
- Dose
- Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
- Population
- Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum MDA was a pre-specified PRIMARY outcome; double-blind, placebo-controlled; MDA measured in serum by colorimetric commercial kit (ZellBio GmbH), intra-assay CV 5.5%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry fundedPermalink
Keep reading
- Everything the graph holds on melatonin
- Every compound studied against Malondialdehyde (circulating)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M0Q303F10R68WCFV29RNWWN6